Nvidia and Eli Lilly unveiled a co-innovation AI Lab for drug discovery efforts. Nvidia announced a strategic collaboration ...

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws ...

Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

If you are wondering whether Travere Therapeutics at around US$29.11 is priced for opportunity or risk, the next sections ...

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...

The latest health news highlights Vietnam's cigarette tax initiative, the FDA's review extension for Travere's kidney drug, ...

An extension was required to provide time to review additional data requested by the FDA to clarify sparsentan’s clinical benefit.

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Travere Therapeutics (TVTX – Research Repo ...

US stock market today: The benchmark indices on Wall Street — Dow Jones, S&P 500, and Nasdaq opened on a mixed note as ...

A fresh setback on the regulatory front was the development that put a damper on Travere Therapeutics ( TVTX 14.63%) stock on ...

Major stock indexes ended lower Tuesday, a day after the S&P 500 and Dow Jones Industrial Average set fresh records, as investors digested a consumer inflation reading that matched expectations and ...